-
Mashup Score: 3IAS 2025: HIV care is political: early focus on the funding crisis | HTB | HIV i-Base - 4 day(s) ago
On 8 July 2025, a press briefing held a week before the IAS 2025 conference brought an appropriate focus on the current crisis in international funding. [1] Dr Beatriz Grinsztejn, IAS President, emphasised the importance of the conference being held in Rwanda this year, because Africa is one of the regions where devastating global funding cuts will be felt most deeply. The conference will be a chance for all stakeholders – scientists, researchers, advocates, affected communities and governments to focus
Source: i-base.infoCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 8New mpox vaccination sites open in the UK | HTB | HIV i-Base - 5 month(s) ago
On 3 February 2025, NHS England announced 12 new mpox vaccination sites. Until recently, the vaccine was only available from clinics in London, Manchester and Brighton. Eligibility criteria for gay and bisexual men includes having multiple partners, group sex, or visiting sex-on-premises venues. Staff at these venues might also be eligible. Vaccine appointments will be available at the sites listed on the NHS online site finder, with the number expected to increas e. The new locations are: Birmingham
Source: i-base.infoCategories: General Medicine News, Infectious DiseaseTweet-
RT @HIViBase: #Mpox news @NHSEngland announces 12 new mpox vaccination sites: https://t.co/98mHSy60fD https://t.co/zFYduDjtOL
-
-
Mashup Score: 3IAS public letter: Why HIV could be poised for a monumental comeback | HTB | HIV i-Base - 5 month(s) ago
This year the IAS annual letter was posted online just after the US threatened to jeopardise PEPFAR and USAID. Undermining science and human rights risks reversing progress and invites the next pandemics. The re-emergence of mpox and H5N1 bird flu are warning shots – HIV could be next. Links to other websites are current at date of posting but not maintained.
Source: i-base.infoCategories: General Medicine News, Infectious DiseaseTweet-
RT @HIViBase: IAS Annual Letter - why #HIV could be poised for a monumental comeback: https://t.co/xINMDNPKHR @iasociety: To end the pande…
-
-
Mashup Score: 3Glasgow 2024: Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48 | HTB | HIV i-Base - 8 month(s) ago
Glasgow 2024 included 48-week results from a randomised placebo-controlled phase 2 switch study comparing once-weekly islatravir plus lenacapavir (ISL+LEN) to a control group who continued on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). [1] This extended data from a phase 2 study out to 48 weeks earlier — 24 week results having been presented at CROI earlier this year. [2, 3] This study randomised 104 participants (1:1) on stable ART to either change to islatravir (2 mg) plus lenacapavir
Source: i-base.infoCategories: General Medicine News, Infectious DiseaseTweet-
RT @HIViBase: Once-weekly #islatravir plus #lenacapavir sustains high efficacy: https://t.co/ATM8ddFQfi Week 48 results include 94% remai…
-
-
Mashup Score: 3Liverpool University Drug Interaction website recognised for global impact on research and care | HTB | HIV i-Base - 8 month(s) ago
This year the Glasgow Congress included the distinction of an official visit from the Princess Royal, to celebrate the 25th anniversary of the Liverpool University Drug Interaction website and its unique contribution to global health. The website was formally launched in 1999 when the expanding complexity of many early HIV combinations included a bewildering range of potential drug interactions with only a limited number of formal interaction studies. Professor David Back worked with Professor Saye Khoo
Source: i-base.infoCategories: General Medicine News, Infectious DiseaseTweet-
RT @hivinteractions: A really lovely write-up of our recognition at #glasgow2024 from @HIViBase 💖 https://t.co/1CJJR9lRkR Thank you so much…
-
-
Mashup Score: 10Glasgow HIV Congress 2024 | HTB | HIV i-Base - 8 month(s) ago
10–13 November 2024, Glasgow. The Glasgow HIV Congress, held every two years to alternate with EACS, is popular for its strong focus on European research and having a diverse single-track programme. In addition to state-of-the-ART plenary overviews and oral talks that often present data before it is seen at CROI, the conference includes more than 400 posters. The programme is available on the conference website and the abstract book is published as an open access supplement to the Journal of the IAS. [1,
Source: i-base.infoCategories: General Medicine News, Infectious DiseaseTweet-
RT @HIViBase: i-Base reports from this year’s dynamic @HIVGlasgow meeting Please see https://t.co/EMwqCk5LKP for early reports on latest #…
-
-
Mashup Score: 19Event-based dosing | Guides | HIV i-Base - 1 year(s) ago
Event-based dosing involves only using PrEP when you want to have sex. Start with a double dose (two pills) at least two hours before you are going to have sex. However, instead of continuing to take daily PrEP you only continue for either two or seven days – depending on the type of sex you have. If you continue having sex for several days, just keep taking a daily pill. Then continue daily PrEP after the last day you last have sex for either either 2 or 7 days Event-based dosing is just as effective as
Source: i-base.infoCategories: General Medicine News, HIV/AIDSTweet-
Dan Clutterbuck highlights the @HIViBase PrEP guidance double dose start for all Best predictor of PrEP efficacy is PBMC concentrations Link to guidance: https://t.co/ErEbqlhifm. #BHIVA24 https://t.co/Eabtlwfw7r
-
-
Mashup Score: 77
The 10th edition of this guide includes significant changes that make PrEP easier to take. This is an exciting time for PrEP. Everyone who can benefit from PrEP in the UK should now be able to get it at an NHS clinic. You no longer have to be at high risk. Everyone now has the option to quick-start PrEP using a double first dose (two pills), working within two hours. Event-based dosing can also now be used by everyone. This uses either 2:1:1 or 2:7 dosing. New info covers starting and stopping PrEP and
Source: i-base.infoCategories: General Medicine News, Infectious DiseaseTweet-
The UK PrEP guide is now available on line. Major changes: PrEP in the UK available to everyone who requests it; option to quick-start PrEP using a double first dose; event-based (2:1:1 or 2:7) dosing; use of new versions of PrEP (TAF/FTC & injectables). https://t.co/1rNy8VQ8vI
-
-
Mashup Score: 1Future meetings and webinars 2023/24 | HTB | HIV i-Base - 2 year(s) ago
The following listing covers selected upcoming HIV-related meetings and workshops. Registration details, including for community and community press are included on the relevant websites. Some meetings are in person, some are virtual and others offer both options. Academic Medical Education (AME) meetings and workshops Several AME workshops (previously Virology Education) are highlighted below but 35 meetings are planned each year. Many virtual meetings include free registrations for health workers,
Source: i-base.infoCategories: HIV/AIDS, Latest HeadlinesTweet-
RT @HIViBase: HTB August 2023. Future meetings: Future meetings and webinars. https://t.co/4dW0RziRUk @ukcab @4Mproject @GeorgeHouseTrst…
-
-
Mashup Score: 1BHIVA include efficacy data on HIV and monkeypox vaccine: updated statement | HTB | HIV i-Base - 3 year(s) ago
Simon Collins, HIV i-Base On 17 August 2022, BHIVA issued an updated statement on monkeypox (MPX) that includes information about vaccine efficacy, including in people living with HIV. [1] The statement summarises information about the time to develop antibody responses and that these continue to increase over four weeks after a single shot. One of the two HIV studies includes that responses…
Source: i-base.infoCategories: HIV/AIDS, Latest HeadlinesTweet-
RT @HIViBase: @BritishHIVAssoc Include efficacy data on #HIV and #monkeypox vaccine: updated statement. https://t.co/T7JvJ8Jj5n (2/3)
-
RT @HIViBase: #IAS2025: #HIVcare is political: early focus on the funding crisis: https://t.co/ugFyFgDBou Opening press conference shows…